{"id":2661,"date":"2019-06-01T12:04:00","date_gmt":"2019-06-01T10:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/rekordhoch-bei-den-von-der-fda-in-den-usa-neu-zugelassenen-arzneimitteln-im-jahr-2018"},"modified":"2019-06-01T12:04:00","modified_gmt":"2019-06-01T10:04:00","slug":"rekordhoch-bei-den-von-der-fda-in-den-usa-neu-zugelassenen-arzneimitteln-im-jahr-2018","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/rekordhoch-bei-den-von-der-fda-in-den-usa-neu-zugelassenen-arzneimitteln-im-jahr-2018","title":{"rendered":"Rekordhoch bei den von der FDA in den USA neu zugelassenen Arzneimitteln im Jahr 2018"},"content":{"rendered":"<p>Wie jedes Jahr ist in \u201eNature Reviews Drug Discovery\u201c im Februar eine \u00dcbersicht erschienen zu den 2018 von der Lebensmittel\u00fcberwachungs- und Arzneimittelbeh\u00f6rde der USA (Food and Drug Administration = FDA) zugelassenen neuen Arzneimittel (1). Mit 59 neu zugelassenen Arzneimitteln wurde der bisherige Rekord aus dem Jahr 1996 (53 neu zugelassene Arzneimittel) deutlich \u00fcbertroffen. Dabei best\u00e4tigen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wie jedes Jahr ist in \u201eNature Reviews Drug Discovery\u201c im Februar eine \u00dcbersicht erschienen zu den 2018 von der Lebensmittel\u00fcberwachungs- und Arzneimittelbeh\u00f6rde der USA (Food and Drug Administration = FDA) zugelassenen neuen Arzneimittel (1). Mit 59 neu zugelassenen Arzneimitteln wurde der bisherige Rekord aus dem Jahr 1996 (53 neu zugelassene Arzneimittel) deutlich \u00fcbertroffen. Dabei best\u00e4tigen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5229,255,5231,2943,5228,5090,5092,5230,5225,5234,257,5232,5233,5227,5226],"class_list":["post-2661","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-apalutamid","tag-arzneimittel","tag-bictegravir","tag-blockbuster","tag-cemiplimab","tag-erenumab","tag-fremanezumab","tag-galcanezumab","tag-lanadelumab","tag-larotrectinib","tag-medikamente","tag-moxidectin","tag-patisiran","tag-tafenoquin","tag-zolgensma"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2661"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2661\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}